Literature DB >> 4748449

The basis for the disparate sensitivity of L1210 leukemia and Walker 256 carcinoma to a new triazine folate antagonist.

R T Skeel, W L Sawicki, A R Cashmore, J R Bertino.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1973        PMID： 4748449

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  3 in total

1.  A phase I and pharmacokinetic study of trimetrexate using a 24-hour continuous-injection schedule.

Authors:  C J Allegra; J Jenkins; R B Weiss; F Balis; J C Drake; J Brooks; R Thomas; G A Curt
Journal:  Invest New Drugs       Date:  1990-05       Impact factor: 3.850

2.  Phase II study of Baker's antifol (triazinate, TZT, NSC 139, 105) in advanced carcinoma of the ovary. A Gynecologic Oncology Group study.

Authors:  J C Arseneau; B Bundy; H Homesley; J Beecham
Journal:  Invest New Drugs       Date:  1983       Impact factor: 3.850

3.  Cross resistance to esters of methotrexate in a doxorubicin-resistant subline of P388 murine leukemia.

Authors:  A Ramu; M Fridkin; R Steinherz
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.